Kyushu University Academic Staff Educational and Research Activities Database
Search by Keyword How ro search
Keyword
Search Criteria
 
Detailed Search

Researcher information (To researchers) Need Help? How to update
Yamaguchi Tomokazu Last modified date：2024.04.22

Assistant Professor / Pharmacology
Department of Basic Medicine
Faculty of Medical Sciences




E-Mail　*Since the e-mail address is not displayed in Internet Explorer, please use another web browser:Google Chrome, safari.
Homepage
https://kyushu-u.elsevierpure.com/en/persons/tomokazu-yamaguchi
　Reseacher Profiling Tool　Kyushu University Pure
Phone
092-642-6082
Fax
092-642-6083
Academic Degree
Doctor of Science
Country of degree conferring institution (Overseas)
No
Field of Specialization
medical science
ORCID(Open Researcher and Contributor ID)
0000-0002-8362-0031
Total Priod of education and research career in the foreign country
00years00months
Research
Research Interests
  • Dissecting the physiological role of CCR4-NOT complex regulating RNA metabolism in homeostasis of cardiac functions.
    keyword : CNOT6L, CCR4-NOT complex, Heart failure, Cardiac fibrosis
    2020.04～2023.06.
Academic Activities
Papers
 Show All Papers >>
Presentations
 Show All Presentations >>
1. Angiotensin-converting enzyme 2 (ACE2) is the carboxypeptidase that degrades angiotensin II (Ang II) and improves the pathologies of cardiovascular disease and acute respiratory distress syndrome (ARDS)/acute lung injury. B38-CAP, a carboxypeptidase derived from Paenibacillus sp. B38, is an ACE2-like enzyme to decrease angiotensin II levels in mice and ameliorates hypertension and heart failure (Nat Commun. 2020). Here we show the therapeutic effects of B38-CAP on acute lung injury induced by abdominal sepsis, acid aspiration, or SARS_CoV2 infection. ACE2 expression was downregulated in the lungs of hamsters with SARS-CoV2 infection, or the lungs of mice with cecal ligation puncture (CLP)-induced sepsis or acid-induced lung injury thereby leading to upregulation of Ang II levels. Intraperitoneal injection of B38-CAP decreased Ang II levels and suppressed the pathologies of lung inflammation, improved lung dysfunction, and downregulated elevated cytokine mRNA levels in acute lung injury in these animal models. Thus, systemic treatment with an ACE2-like enzyme might be a potential therapeutic strategy for patients with severe sepsis or ARDS (Nat Commun. 2021; PLoS One. 2022)..


Unauthorized reprint of the contents of this database is prohibited.

Copyright © 2006, Kyushu University. All rights reserved.